Argos Therapeutics Inc

Type: Company
Name: Argos Therapeutics Inc
First reported Sep 19 2014 - Updated Sep 19 2014 - 2 reports

Argos Therapeutics to Present at the 21st Annual BioCentury NewsMakers Conference

DURHAM, N.C., Sept. 19, 2014 (GLOBE NEWSWIRE) -- . (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis ... [Published Industrial Info Financials - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Enrollment in Argos Therapeutics' Pivotal Phase III ADAPT Trial of AGS-003 for Metastatic Renal Cell Carcinoma Surpasses Fifty Percent

DURHAM, N.C., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. ( Nasdaq:ARGS ), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases ... [Published Securities Technology Monitor - Sep 18 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Argos Announces Issuance of Arcelis(R) Technology Platform Patent

DURHAM, N.C., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. ( Nasdaq:ARGS ), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases ... [Published WGNT - Sep 08 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Gene Therapy May Hold Key to HIV Cure, If Government Allows It

An innovative patient-specific immunotherapy offers a new and promising strategy for fighting HIV, making it possible for patients to suppress the virus even after stopping drug treatment.Biopharmaceutical company Argos Therapeutics presented the results ... [Published Gay.com - Sep 04 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 2 reports

Argos Therapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

DURHAM, N.C., Sept. 3, 2014 (GLOBE NEWSWIRE) -- . (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ ... [Published Pettinga Financial Advisors - Sep 03 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Argos Signs for New Build-to-Suit HQs

Argos Therapeutics Inc. entered into a lease with TKC LXXII LLC for land and a 97,500-square-foot building to be constructed on 11 acres in Durham, North Carolina.The facility will house its corporate headquarters and primary manufacturing facility.The ... [Published CoStar Group - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Argos Therapeutics Rating Lowered to Neutral at Zacks (ARGS)

Argos Therapeutics (NASDAQ:ARGS) remained flat at $8.75 during trading on Wednesday. 29,311 shares of the company’s stock traded hands. Argos Therapeutics has a 1-year low of $5.611 and a 1-year high of $13.74. The stock has a 50-day moving average of ... [Published American Banking News - Stock Ratings - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Argos formally picks Durham for HQ, signs 10-year lease

Posted Aug. 25, 2014 at 7:17 a.m. Argos' immunotherapy process as explained in an animation at its website. Image 1 of 2 · Next Image…By WRAL TechWireDurham, N.C. — Argos Therapeutics, which went public earlier this year, has formally committed to making ... [Published Local Tech Wire - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

The Keith Corp. to build new Argos Therapeutics HQ in Durham

Argos Therapeutics has reached a deal with Charlotte real estate developer The Keith Corp. to build a new headquarters office and manufacturing facility in Durham.Under the terms of the 10-year lease agreement, Argos will lease a 97,500-square-foot building ... [Published Business First of Buffalo - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Argos Therapeutics commits to new headquarters in Durham

Argos Therapeutics has reached a deal with a Charlotte real estate developer to build a new headquarters office and manufacturing facility in Durham.Under the terms of the 10-year lease agreement with Charlotte-based The Keith Corp., Argos will lease ... [Published Business First of Buffalo - Aug 22 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Argos leases Durham County land for new building

Argos Therapeutics has leased 11 acres of land in Durham County where it plans to build a 97,500-square-foot building, the company reported in a regulatory filing this week.Click to Continue » ... [Published Raleigh News & Observer - Aug 22 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 2 reports

Research Analysts’ New Coverage for August, 19th (ACOR, ARGS, BIIB, BIND, DNKN, DSCO, ECI, FARO, HCG, KITE)

Research Analysts’ new coverage for Tuesday, August 19th:Stifel Nicolaus initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR)Stifel Nicolaus began coverage on shares of Argos Therapeutics (NASDAQ:ARGS)Stifel Nicolaus initiated coverage on ... [Published American Banking News - Aug 19 2014]

Quotes

...trally-acting kappa agonist molecules," said Stephen K Doberstein, Ph D , senior vice president and chief scientific officer of Nektar Therapeutics. "With this research, we are continuing to capitalize on the ability of our small molecule polymer medicinal chemistry platform to create new peripherally-acting molecules that could address different pain conditions."
...immunotherapy in newly diagnosed, synchronous metastatic RCC patients," said Robert A Figlin, MD, FACP, primary investigator for the ADAPT trial. "We remain encouraged by the potential for AGS-003 to represent an important advance for the immunotherapy field as well as the treatment of advanced RCC in the years ahead."
According to Jeff Abbey, chief executive officer at Argos, "This patent significantly expands the protection of our proprietary Arcelis ® technology platform relating to the maturation method used in the manufacture of our dendritic cell immunotherapies for treatment of cancer and infectious disease. This patent relates to production of our two lead investigational immunotherapies, AGS-003 for metastatic renal cell carcinoma (mRCC) and AGS-004 for HIV infection."
...conveys both stature and status upon its steadily growing roster of tenants," said Jonathan (Jody) Durst, president of The Durst Organization. "By leasing a full floor in one of the world’s most prominent office buildings, Servcorp is making a smart business decision that will yield benefits for the company for many years to come."

More Content

All (58) | News (30) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (18)
sort by: Date | Relevance
Nektar Presents Positive Preclinical Data on Ka... [Published BioMedReports - Sep 20 2014]
Argos Therapeutics to Present at the 21st Annua... [Published GlobeNewswire: Acquisitions News - Sep 19 2014]
Argos Therapeutics to Present at the 21st Annua... [Published Industrial Info Financials - Sep 19 2014]
Argos Therapeutics to Present at the 21st Annua... [Published Fat Pitch Financials - Sep 19 2014]
Enrollment in Argos Therapeutics' Pivotal Phase... [Published GlobeNewswire: Advertising News - Sep 18 2014]
Enrollment in Argos Therapeutics' Pivotal Phase... [Published Securities Technology Monitor - Sep 18 2014]
Argos Announces Issuance of Arcelis(R) Technolo... [Published GlobeNewswire: Advertising News - Sep 08 2014]
Argos Announces Issuance of Arcelis(R) Technolo... [Published WGNT - Sep 08 2014]
Gene Therapy May Hold Key to HIV Cure, If Gover... [Published Gay.com - Sep 04 2014]
Argos Therapeutics to Present at the Rodman & R... [Published GlobeNewswire: Acquisitions News - Sep 03 2014]
Argos Therapeutics to Present at the Rodman & R... [Published Pettinga Financial Advisors - Sep 03 2014]
Argos Therapeutics to Present at the Rodman & R... [Published WGNT - Sep 03 2014]
Argos Signs for New Build-to-Suit HQs [Published CoStar Group - Aug 29 2014]
Lease Up (Aug. 25-29) Toyota Continues U.S. Fac... [Published CoStar Group - Aug 29 2014]
Argos Therapeutics Rating Lowered to Neutral at... [Published American Banking News - Stock Ratings - Aug 27 2014]
Argos formally picks Durham for HQ, signs 10-ye... [Published Local Tech Wire - Aug 25 2014]
The Keith Corp. to build new Argos Therapeutics... [Published Business First of Buffalo - Aug 25 2014]
Oragenics: Interview With CEO Bonfiglio [Published Seeking Alpha - Aug 24 2014]
Argos Therapeutics commits to new headquarters ... [Published Business First of Buffalo - Aug 22 2014]
Argos leases Durham County land for new building [Published Raleigh News & Observer - Aug 22 2014]
6 Biotech Stocks to Buy Now With Up to 100% Ups... [Published Yahoo! Xtra Business - Aug 20 2014]
Council approves Argos incentives [Published Durham Herald-Sun - Aug 19 2014]
Top Analysts Action: URBN, EAT, LXRX, SCTY, IR [Published BayStreet.ca - Aug 19 2014]
Research Analysts’ New Coverage for August, 19t... [Published American Banking News - Aug 19 2014]
Argos Therapeutics Research Coverage Started at... [Published American Banking News - Forex - Aug 19 2014]
ARGOS THERAPEUTICS INC - 10-Q - Management's Di... [Published Wall Street Business Network - Aug 14 2014]
Argos Therapeutics Reports Second Quarter 2014 ... [Published GlobeNewswire: Advertising News - Aug 13 2014]
Argos Therapeutics to Hold Second Quarter 2014 ... [Published GlobeNewswire: Acquisitions News - Aug 06 2014]
Argos Therapeutics Presents Data Showing the Im... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
Argos Therapeutics to Present at Two Upcoming H... [Published GlobeNewswire: Advertising News - Jun 11 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
#PCTUS: 8 Facts from Day 2 [Published Partnerships in Clinical Trials - Apr 02 2014]
Throughout the second day of Partnerships in Clinical Trials , one word was a trending topic throughout the presentations:   communication .   Communication is key among all stakeholders in the clinical trials field to keep trials on a timeline and ...
Argos Therapeutics presents new data from clini... [Published PBR - News - Mar 05 2014]
Argos Therapeutics has presented data from clinical studies of AGS-004, the company's patient-specific immunotherapy currently in development for the treatment of HIV infection. ...
Financings of the Fortnight And the Neverending... [Published The IN VIVO Blog - Feb 21 2014]
Somewhere out there, perhaps, is the end of NovImmune's Series B round.More than a year ago, our friends at START-UP examined the fates of biotechs that had reeled in huge private financing rounds. Giant biotech venture rounds are back with a buzz ...
Forbion Announces Closing of Public Offering of... [Published Business Wire Science: Science News - Feb 20 2014]
NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics has closed its initial public offering. ...
Forbion Announces Closing of Public Offering of... [Published Business Wire Health News - Feb 20 2014]
NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics has closed its initial public offering. ...
1 2

Press Releases

sort by: Date | Relevance
Argos Therapeutics to Present at the 21st Annua... [Published GlobeNewswire: Acquisitions News - Sep 19 2014]
Enrollment in Argos Therapeutics' Pivotal Phase... [Published GlobeNewswire: Advertising News - Sep 18 2014]
Argos Announces Issuance of Arcelis(R) Technolo... [Published GlobeNewswire: Advertising News - Sep 08 2014]
Argos Therapeutics to Present at the Rodman & R... [Published GlobeNewswire: Acquisitions News - Sep 03 2014]
Argos Therapeutics Reports Second Quarter 2014 ... [Published GlobeNewswire: Advertising News - Aug 13 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.